Literature DB >> 17372906

Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas.

Yoshimasa Nobeyama1, Eriko Okochi-Takada, Junichi Furuta, Yohei Miyagi, Kanako Kikuchi, Akifumi Yamamoto, Yukihiro Nakanishi, Hidemi Nakagawa, Toshikazu Ushijima.   

Abstract

To identify tumor-suppressor genes inactivated by aberrant methylation of promoter CpG islands (CGIs) in human malignant melanomas, genes upregulated by treatment of cells with a demethylating agent, 5-aza-2'-deoxycytidine (5-aza-dC), were searched for using oligonucleotide microarrays in melanoma cell lines, HMV-I, MeWo and WM-115. Seventy-nine known genes with CGIs were identified as being upregulated (>or=16-fold), and 18 of them had methylation of their putative promoter CGIs in 1 or more of 8 melanoma cell lines. Among the 18 genes, TFPI-2, which is involved in repression of the invasive potential of malignant melanomas, was further analyzed. Its expression was repressed in a melanoma cell line with its complete methylation, and was restored by 5-aza-dC treatment. It was unmethylated in cultured neonatal normal epidermal melanocyte, and was induced by ultraviolet B. In surgical melanoma specimens, TFPI-2 methylation was detected in 5 of 17 metastatic site specimens (29%), while it was not detected in 20 primary site specimens (0%) (p=0.009). By immunohistochemistry, the 5 specimens with promoter methylation lacked immunoreactivity for TFPI-2. The results showed that TFPI-2 is silenced in human malignant melanomas by methylation of its promoter CGI and suggested that its silencing is involved in melanoma metastasis. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17372906     DOI: 10.1002/ijc.22637

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  Methylation of TFPI-2 is an early event of esophageal carcinogenesis.

Authors:  Yan Jia; Yunsheng Yang; Malcolm V Brock; Baoping Cao; Qimin Zhan; Yazhuo Li; Yuanzi Yu; James G Herman; Mingzhou Guo
Journal:  Epigenomics       Date:  2012-04       Impact factor: 4.778

Review 2.  Impact of venous thromboembolism and anticoagulation on cancer and cancer survival.

Authors:  Nicole M Kuderer; Thomas L Ortel; Charles W Francis
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

Review 3.  Genetic and epigenetic marker-based DNA test of stool is a promising approach for colorectal cancer screening.

Authors:  Sung Whan An; Nam Kyu Kim; Hyun Cheol Chung
Journal:  Yonsei Med J       Date:  2009-06-23       Impact factor: 2.759

4.  Integrative genome comparison of primary and metastatic melanomas.

Authors:  Omar Kabbarah; Cristina Nogueira; Bin Feng; Rosalynn M Nazarian; Marcus Bosenberg; Min Wu; Kenneth L Scott; Lawrence N Kwong; Yonghong Xiao; Carlos Cordon-Cardo; Scott R Granter; Sridhar Ramaswamy; Todd Golub; Lyn M Duncan; Stephan N Wagner; Cameron Brennan; Lynda Chin
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

5.  Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies.

Authors:  Luca Sigalotti; Alessia Covre; Elisabetta Fratta; Giulia Parisi; Francesca Colizzi; Aurora Rizzo; Riccardo Danielli; Hugues J M Nicolay; Sandra Coral; Michele Maio
Journal:  J Transl Med       Date:  2010-06-11       Impact factor: 5.531

6.  Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion.

Authors:  Sophie Iochmann; Claire Bléchet; Valérie Chabot; Annabelle Saulnier; Aniça Amini; Guillaume Gaud; Yves Gruel; Pascale Reverdiau
Journal:  Clin Exp Metastasis       Date:  2009-03-07       Impact factor: 5.150

7.  CpG island methylator phenotype predicts progression of malignant melanoma.

Authors:  Atsushi Tanemura; Alicia M Terando; Myung-Shin Sim; Anneke Q van Hoesel; Michiel F G de Maat; Donald L Morton; Dave S B Hoon
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

8.  Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer.

Authors:  Sabine C Glöckner; Mashaal Dhir; Joo Mi Yi; Kelly E McGarvey; Leander Van Neste; Joost Louwagie; Timothy A Chan; Wolfram Kleeberger; Adriaan P de Bruïne; Kim M Smits; Carolina A J Khalid-de Bakker; Daisy M A E Jonkers; Reinhold W Stockbrügger; Gerrit A Meijer; Frank A Oort; Christine Iacobuzio-Donahue; Katja Bierau; James G Herman; Stephen B Baylin; Manon Van Engeland; Kornel E Schuebel; Nita Ahuja
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

9.  Expression array analysis of the hepatocyte growth factor invasive program.

Authors:  Fabiola Cecchi; Chih-Jian Lih; Young H Lee; William Walsh; Daniel C Rabe; Paul M Williams; Donald P Bottaro
Journal:  Clin Exp Metastasis       Date:  2015-08-01       Impact factor: 5.150

10.  Tissue factor pathway inhibitor-2 inhibits the growth and invasion of hepatocellular carcinoma cells and is inactivated in human hepatocellular carcinoma.

Authors:  Yong Xu; Xiaolin Qin; Jinjing Zhou; Zhiguang Tu; Xiao Bi; Wuxian Li; Xiaoqing Fan; Yi Zhang
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.